Tag Archives: HR-Positive Breast Cancer

Roche’s Itovebi Regimen Shows Significant Survival Benefits for HR-Positive Breast Cancer in Phase III Trial Results

(IN BRIEF) Roche announced the publication of pivotal phase III results for its Itovebi™ (inavolisib)-based regimen at the Clinical Trials in Alzheimer’s Disease congress, demonstrating a 57% reduction in the risk of disease progression or death in patients with HR-positive, … Read the full press release